Full Name
Dr Bernard Escudier
Job Title
MD
Company
Gustave Roussy
Speaker Bio
Bernard Escudier, MD, is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, France. Dr. Escudier’s research focuses on renal cell carcinoma, immunotherapy and on development of new therapeutic strategies.
Dr. Escudier received his medical degree from the University of Paris, Paris, France, and initially trained as a cardiologist and then an intensivist. He became the head of the first immunotherapy unit in Gustave Roussy in 1992, and then moved to the Medical Oncology Department.
He is currently member of the GU Group, and also acts as mediator for the institution.
He has authored more than 540 publications in peer-reviewed journals and is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the European Society for Medical Oncology. He is also a member of the board of the Kidney Cancer Association and president of ARTuR (the French association on renal tumors).
Dr. Escudier has been the head of the French Group of Immunotherapy from 1992 to 2012, which conducts large multicenter phase 2/3 studies in renal cancer; he is also a principal investigator for many phase 1 to 3 clinical trials in renal cancer. He has been part of the development of every new agent from cytokines to VEGF/mTOR taregted agents and more recently new immunotherapy.
Dr. Escudier received his medical degree from the University of Paris, Paris, France, and initially trained as a cardiologist and then an intensivist. He became the head of the first immunotherapy unit in Gustave Roussy in 1992, and then moved to the Medical Oncology Department.
He is currently member of the GU Group, and also acts as mediator for the institution.
He has authored more than 540 publications in peer-reviewed journals and is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the European Society for Medical Oncology. He is also a member of the board of the Kidney Cancer Association and president of ARTuR (the French association on renal tumors).
Dr. Escudier has been the head of the French Group of Immunotherapy from 1992 to 2012, which conducts large multicenter phase 2/3 studies in renal cancer; he is also a principal investigator for many phase 1 to 3 clinical trials in renal cancer. He has been part of the development of every new agent from cytokines to VEGF/mTOR taregted agents and more recently new immunotherapy.
Speaking At
